Pay in 4 interest-free payments of $10.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Epizyme has initiated a Phase 1/2 clinical trials targeting the treatment of non-Hodgkin lymphoma
CAS Number: 354813-19-7
visible nuclei and more noticeable bile canaliculi between hepatocytes
Effect of DNA damage response by quinazolinone analogue HMJ-38 on human umbilical vein endothelial cells: Evidence for γH2A
p300 and CBP are transcriptional co-activators that modulate DNA replication
BAY 87-2243 - Hypoxia-inducible Factor-1 (HIF-1) Inhibitor. CAS# 1227158-85-1 60069 Epizyme has initiated a PhaseBAY 87 2243, CAS No. 1227158 85 1, is a highly potent and selective inhibitor of hypoxia induced gene activation, which has antitumor activities by inhibition of mitochondrial complex I. BAY 87 2243 mproves local tumor control after fractionated irradiation in a schedule dependent manner in head and neck human xenografts. BAY 87 2243 markedly decreased nuclear HIF 1 expression and pimonidazole hypoxic fraction already after 3 days of drug treatment.
US$ 59.99
US$ 159.99
US$ 2097.50
US$ 64.95
US$ 2197.50
US$ 2249.50
US$ 89.95
US$ 3997.50
US$ 4097.50
US$ 33.89